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ABSTRACT
The aim of this study was to estimate the costs of treatment of children who present with the signs and 
symptoms of invasive bacterial diseases in Khanh Hoa province, Viet Nam. The study was an incidence-
based cost-of-illness analysis from the health system perspective. The hospital costs included labour, ma-
terials and capital costs, both direct and indirect. Costs were determined for 980 children, with an average 
age of 12.67 months (standard deviation±11.38), who were enrolled in a prospective surveillance at the 
Khanh Hoa General Hospital during 2005-2006. Of them, 57% were male. By disease-category, 80% were 
suspected of having pneumonia, 8% meningitis, 3% very severe disease consistent with pneumococcal sep-
sis, and 9% other diseases. Treatment costs for suspected pneumonia, meningitis, very severe disease, and 
other diseases were US$ 31, US$ 57, US$ 73, and US$ 24 respectively. Costs ranged from US$ 24 to US$ 164 
across different case-categories. Both type of disease and age of patient had statistically significant effects 
on treatment costs. The results showed that treatment costs for bacterial diseases in children were consid-
erable and might differ by as much as seven times among invasive pneumococcal diseases. Changes in 
costs were sensitive to both age of patient and case-category. These cost-of-illness data will be an important 
component in the overall evidence base to guide the development of vaccine policy in Viet Nam.
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INTRODUCTION
Globally, nearly two million children die each year 
due to acute respiratory tract infections (ARIs) (1). 
Besides, an estimated 150 million episodes of child-
hood pneumonia occur, of which 11-20 million 
require hospitalization (2). The incidence of pneu-
monia among children aged less than five years 
is estimated to be 0.29 episodes per child-year in 
developing and 0.05 episodes per child-year in de-
veloped countries (2). Recent estimates from the 
United Nations Children’s Fund suggest that Strep-
tococcus pneumoniae causes half of all deaths due to 
pneumonia in children, and 70% of these deaths 
occur in Africa and Asia (3). A large proportion of 
these deaths could be averted through routine im-
munization using available pneumococcal conju-
gate vaccines (4,5). However, a substantial barrier 
to the use of pneumococcal conjugate vaccine is 
the non-availability of adequate information on 
costs associated with treatment of clinical condi-
tions consistent with invasive pneumococcal dis-
eases in children. In addition, an increasing num-
ber of countries are now requesting or requiring 
cost-of-illness data on vaccine-preventable diseases 
before making long-term commitments for the 
introduction of new vaccines. At present, only a 
limited number of studies reported costs associated 
with syndromes of invasive bacterial infections in 
children from developing countries (6-8). To ad-
dress this gap in information, we determined costs 
for the treatment of invasive bacterial infection 
syndromes in children in Nha Trang, Viet Nam.Anh DD et al. Treatment cost of suspected pneumococcal diseases
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MATERIALS AND METHODS
Study design and data collection
We conducted an incidence-based cost-of-illness 
analysis from the healthcare system perspective, a 
technique used for measuring the economic bur-
den of patients from the onset to the end of illness 
(9,10). We selected the Khanh Hoa General Hos-
pital (KHGH) for this study in Nha Trang city, the 
capital of Khanh Hoa province, Viet Nam. During 
2005-2006, a prospective surveillance for clinical 
syndromes associated with invasive pneumococ-
cal diseases was conducted at the KHGH; its results 
were published elsewhere (11). Before the enroll-
ment of study patients, all clinicians and medical 
staff of the Department of Pediatrics and Infectious 
Diseases of KHGH were provided with standardized 
procedures and screening criteria for identifying 
children with pneumonia, meningitis, sepsis, and 
other syndromes consistent with invasive bacterial 
diseases. After the completion of informed consent 
procedures, appropriate clinical specimens (blood 
and/or cerebrospinal fluid) were obtained, and par-
ents were interviewed to collect demographic in-
formation and illness history. All specimens were 
tested using bacterial culture methods, and selected 
specimens underwent further testing by antigen de-
tection and polymerase chain reaction. Definitions 
of diseases were based on the published guidelines 
(12-13), and patients’ demographics and clinical 
characteristics were drawn from the published re-
search report (11).
Costing methods
For our analysis, cost-of-illness was defined as the 
sum of direct medical, direct non-medical, and in-
direct costs (9). Direct medical cost was defined as 
costs directly associated with provision of health-
care, including costs for detection, treatment, con-
tinuing care, rehabilitation, and terminal care. For 
this study, we focused our analysis on direct medi-
cal or treatment costs employing the micro-costing 
approach that estimates costs of treatment by sum-
ming all medical services received by an individual 
patient (14). Vietnamese children, aged less than six 
years, are now covered under a national health in-
surance supported by the Vietnamese government. 
In Viet Nam, public hospitals receive government 
funding in the form of lump sum budget and 
insurance system reimbursements for delivery of 
medical services to patients. Hospitals receive reve-
nue in the form of out-of-pocket payments directly 
from patients (approximately 60% of the total ex-
penditure). For the health insurance, hospital costs 
are reimbursed by the Ministry of Health using a 
fee-for-service system. To collect data on individual 
patient’s cost, the KHGH uses a FoxPro® (Microsoft, 
Redmond, Washington, DC) data-entry system that 
records costs of services provided (e.g. number of 
hospitalization days, laboratory tests, radiographic 
procedures, therapeutic procedures, and drugs) to 
an individual patient.
To compute costs of each medical service, we used 
the ratio of costs to charges (RCCs) method (15,16). 
In this method, the RCC takes into account all 
costs incurred by the hospital and the hospital’s 
total revenue (i.e. patient-charge in the form of 
out-of-pocket payment from uninsured patients 
and reimbursement from the Ministry of Health 
for insured patients). Then, the total annual hospi-
tal costs were divided by total annual revenue (or 
total charges) to derive the overall RCC. We then 
multiplied charges for each service by the RCC to 
obtain costs of a service item for each patient. We 
summed the costs of all medical services and drugs 
of each patient to obtain total direct medical costs 
or treatment costs for each patient. Total hospital 
cost included labour cost of all hospital staff, mate-
rial cost (e.g. use of electrical utilities), and capital 
cost. Capital costs associated with the use of depre-
ciable assets, i.e. equipment, buildings, furnishings, 
and vehicles. The capital cost was calculated based 
on the straight-line equivalent annual economics-
based approach (17). This approach covers both de-
preciation cost (the rate at which the capital asset 
is ‘used up’) and opportunity cost (interest) of mak-
ing the investment (18). The cost is equally allo-
cated to period of useful life. Based on the Ministry 
of Finance guidelines, we assumed that the useful 
life of vehicles, equipment, and buildings was 5, 10 
and 25 years respectively (19). We covered all items 
in use, although they were over official working 
years since they still had opportunity cost (18). We 
applied a 3% discount rate to our cost analysis (18). 
The costs were converted from Viet Nam dong to 
US dollar at the 2006 prices (VND 15,976.83=US$ 
1) (20).
Analysis of data
Demographic information was described by fre-
quency and proportion. We calculated means with 
standard deviations (SDs) for continuous variables 
and used multiple regression analysis to explore 
the factors associated with variations in treatment 
costs. Covariates considered in this modelling 
included age (months), duration of stay (days), and 
diagnosis. In addition, since prices of drugs may 
vary substantially among hospitals, we performed a Anh DD et al. Treatment cost of suspected pneumococcal diseases
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sensitivity analysis to explore the effect of variation 
in prices of antibiotics across a range of prices of 
antibiotics available from the KHGH databases.
RESULTS
Characteristics of patients
Patients’ demographics are presented in Table 1. 
In total, 980 children were enrolled in the study. 
Their average age was 12.67 months (SD±11.38). 
The majority (56.5%) were male. Sixty percent of 
the patients were currently breastfeeding, and 42% 
had received antibiotics during the 14-day period 
before hospital admission. Of the 980 children, 
80.4% were diagnosed with pneumonia, 7.8% with 
meningitis, 3.2% with very severe disease, and 8.7% 
with other diseases. Of the 980 children with a spe-
cific diagnosis, 43.5% were classified as CXR-con-
firmed pneumonia, followed by CXR-confirmed 
severe pneumonia (19.7%) and suspected menin-
gitis (6.7%). All the enrolled patients were treated 
in the inpatient facilities of the KHGH, and the 
average duration of hospitalization was 6.48 days 
(SD±4.14) (Table 2).
The highest costs (mean US$ 164) was incurred for 
definite (i.e. laboratory-confirmed) meningitis, fol-
lowed by probable bacterial meningitis (US$ 121). 
Results of sensitivity analysis showed that treat-
ment costs rose by 8% and decreased by 4% when 
the maximum and minimum prices of antibiotics 
were used for analysis instead of mean prices res- 
pectively. The costs increased by 13% when cal-
culated using maximum compared to minimum 
prices of antibiotics.
To explore the co-factors affecting the treatment 
costs, we conducted a multiple regression analysis 
using age, days of hospitalization, and diagnosis 
as independent variables. All, except days of hos-
pitalization, had significant effects on cost. The 
model had explanation power of 17.2% (adjusted 
R2=0.172). Estimated costs regarding age and di-
agnosis were constructed. The costs of all disease-
groups were inversely related to age—as the age of 
patients increased, costs decreased (Fig.). When we 
compared diagnosis and age-groups, the average 
treatment cost of pneumonia ranged from US$ 18 
to US$ 66. Similarly, the cost of treating meningitis 
ranged from US$ 25 to US$ 190.
DISCUSSION
Characteristics of patients
This study used data on patients from a representa-
tive group of hospitalized children in Viet Nam. As 
in previous studies (21,22), most (94.6%) children 
hospitalized with acute respiratory disease were 
aged less than three years. Analysis of data from the 
prospective surveillance suggests that most (80.4%) 
suspected invasive pneumococcal diseases in Viet-
namese children manifests initially as pneumonia. 
While a few comparative studies across develop-
ing countries have been performed, data from our 
surveillance study in Khanh Hoa province suggest 
that children suffered from various acute lower res-
piratory tract diseases due to respiratory bacteria 
and viruses. While some children with bacterial 
infections may present with less severe disease due 
to prior outpatient treatment with antibiotics, such 
empiric treatment may put the child at risk for 
prolonged disease with antibiotic-resistant bacteria 
or respiratory viruses that do not respond to treat-
ment with antibiotics (23).
Costing of illness
Two previous studies in Pakistan estimated costs 
associated with clinical syndromes of invasive 
pneumococcal disease (24,25). For hospitalized care, 
the healthcare provider spent, on average, US$ 71 
Table 1. Demographic characteristics of study 
patients (n=980)
Characteristics No.  %
Age-group (months)
   ≤11 521  53.2
   12-23 290  29.6
   24-35 116  11.8
   36-47 33  3.4
   48-59 20  2.0
Gender
   Male 554  56.5
   Female 426  43.5
Estimation of costs
To convert the payment to economic cost, the cost-
to-charge ratio method was applied. The KHGH 
had total costs of VND 172,482 million with rev-
enue of VND 151,219 million or a hospital cost-to-
charge ratio of 1.14. Of 48 antibiotics used for treat-
ing the study patients, ceftriaxone, cefotaxime, and 
cefuroxime were the most expensive drugs (Table 
3). These three antibiotics accounted for 38%, 29%, 
and 16% of all the drug costs in the study respec-
tively. The average treatment or direct medical costs 
of pneumonia, meningitis, very severe diseases, 
and other diseases were US$ 31, US$ 57, US$ 73, 
and US$ 24 respectively (Table 2). The cost of drugs 
represented 40-63% of the total treatment costs. Anh DD et al. Treatment cost of suspected pneumococcal diseases
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per episode for pneumonia, US$ 235 for severe 
pneumonia, and US$ 2,043 for meningitis (25). 
Results of another study showed that the average 
treatment cost per episode was US$ 17.77 for pneu-
monia and US$ 125.29 for severe pneumonia (24). 
However, direct comparison of healthcare costs 
across countries is limited by the fact that these 
costs arise from systems with different approaches to 
healthcare delivery, treatment patterns, drug-pric- 
ing, costing of services, and different time periods 
for data analysis. Nevertheless, a comparison of 
trends in costs over time and the proportionate 
distribution of costs are reasonable. As in our 
analysis, data from Pakistan showed that the cost 
of treatment of meningitis was higher than that of 
pneumonia, and cost of treatment of severe pneu-
monia was higher than that of non-severe pneu-
monia. Our data in Viet Nam also showed that 
the cost of treatment of meningitis was approxi-
mately twice compared to that of pneumonia. In 
contrast, this difference in the cost of treatment of 
meningitis compared to that of pneumonia was 
nearly 30-fold in Pakistan. In the subset of patients 
with laboratory-confirmed disease, the cost of treat-
ment of definite meningitis (US$ 163.95) was five 
times higher than that of CXR-confirmed pneumo-
nia (US$ 32.45). Another method of comparison is 
to compare with the country’s economy indicators. 
The average treatment cost (US$ 33.56) was ap-
proximately one-tenth of the Viet Nam per-capita 
gross national product (GNP). The per-capita 1998 
GNP for Viet Nam was US$ 350 (26). 
Table 3. Prices of selected antibiotics and total cost of antibiotic use by patients (n=980)
Antibiotic Vial quantity Average unit price (US$) Total cost (US$) % of total
Ceftriaxone 250 mg 4.24 3,557.82 38.4
Cefotaxime 1 g 1.35 2,704.71 29.2
Cefuroxime 250 mg 0.46 1,469.46 15.8
Ciprofloxacin 200 mg 12.44 181.22 2.0
Others NA NA 1,364.52 14.6
NA=Not applicable
Probable pneumonia  
CXR-conﬁrmed severe pneumonia
Probable very severe pneumonia
CXR-conﬁrmed very severe pneumonia
Suspected meningitis
Probable bacterial meningitis
Deﬁnite meningitis
Very severe disease
Other diseases
Age (months) 
Fig. Age-speciﬁc treatment cost estimated by modelling 
CXR denotes chest radiograph
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Because of limitations in the availability of data, we 
could not determine an accurate count of material 
consumption. Instead, we assumed that quantities 
of materials used were equivalent to the amount 
of materials purchased. Regarding the cost-to-
charge method applied in this study, the accuracy 
decreased if some patient-services were provided 
without charge as total hospital costs covered all 
costs of services produced. Thus, the cost of free 
services, e.g. health education, would be absorbed 
by services for which charges were levied. Accuracy 
was also related to accuracy of price-setting (27). 
This refers to the relative prices of different servic-
es (compared to each other in the same hospital) 
actually reflects the relative resource-use of those 
services, even if the level of those prices is much 
higher than the cost.
We considered resource-consumption patterns and 
the representativeness of the study hospital com-
pared to other hospitals in Viet Nam. In the study 
hospital, costs of materials (54%), labour (28%), 
and capital (18%) were all similar to those of Thai-
land (27-29). For the cost-to-charge ratio, a 2003 
study in the same hospital found that the ratios for 
the laboratory, imaging diagnosis, and the whole 
hospital were 1.45, 0.74, and 0.98 respectively (30). 
The difference might be due to different methods 
used for determining both costs and hospital rev-
enues.
Factors affecting treatment costs
In general, consumption of drugs was positively 
associated with both body-weight and age. Due to 
the relatively low explanatory power of the fitted 
cost model (adjusted R2=0.172), other variables not 
included in our modelling procedures may explain 
variations in cost. In addition, the relationship of 
the independent variables may be confounded by 
age. For example, younger children may be more 
vulnerable to pneumococcal diseases than older 
children. In addition, drug-prescribing behaviours 
may affect both use of certain drugs and costs of 
drugs provided (31). We were unable to include 
factors relating to the attending physician in the 
model tested.
Generalizability
We believe that data used in our analysis are both 
reliable and internally valid. The KHGH has a well-
organized computerized database, from which all 
costing data were drawn. Our findings regarding 
age- and disease-specific treatment costs can be 
used together with age-specific incidence rates for 
such economic evaluations as cost-effectiveness, 
cost-utility, and cost-benefit analyses (32). Age-spe-
cific data are also useful for assessing the most cost-
effective ages for immunizations.
Conclusions
Treatment cost of pneumococcal diseases was con-
siderable in Viet Nam. Costs of suspected/probable 
and confirmed pneumococcal disease were sta-
tistically different as were costs of pneumococcal 
pneumonia and meningitis, which can differ by as 
much as seven times. Age of patient and type of 
disease affect costs of treating pneumococcal dis-
eases in Viet Nam. These data will be important in 
the overall evidence to guide the development of 
vaccine policy in Viet Nam. 
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